In June 2022, Enanta filed a lawsuit against Pfizer in a US district court in Massachusetts, claiming that the big pharma ...

Enanta Pharmaceuticals has initiated legal action against Pfizer (PFE) over a patent infringement related to Paxlovid, ...

WATERTOWN, Mass., August 21, 2025--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage ...

Enanta Pharmaceuticals (NASDAQ:ENTA) announced on Wednesday a lawsuit filed in the EU against Pfizer (NYSE:PFE) and some of ...

Enanta (ENTA) announced that it has filed suit in the Unified Patent Court of the European Union against Pfizer (PFE) and certain of its ...

Enanta will host a conference call and webcast today at 4:30 p.m. ET. The live webcast can be accessed under "Events & Presentations" in the investors section of Enanta’s website.

Enanta Q2, 2022 Earnings Presentation (ir.enanta.com) Since its 2017 approval, Glecaprevir generated royalties totaling $722 million per Enanta's fiscal year ending 09/2021 10-K.

Enanta Pharmaceuticals, Inc., a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced the appointment of Brendan ...

Enanta argued that symptom improvement was similar for both antivirals. EDP-235 could be developed and tested in several COVID-related indications, such as long COVID or as a prophylaxis, Luly said.

Enanta Pharmaceuticals Inc., (Nasdaq: ENTA), whose lead drug candidate is in late-stage trials for hepatitis C, has received a $9.2 million boost for its preclinical program focused on a new form ...